Prospective, open uncontrolled study to evaluate the safety of Depigoid with two pollen combinations ( Grasses/Olea and Grasses/ Parietaria) 2000 DPP/ml in patients with allergic rhinitis or rhinoconjunctivitis with or without seasonal asthma.

Trial Profile

Prospective, open uncontrolled study to evaluate the safety of Depigoid with two pollen combinations ( Grasses/Olea and Grasses/ Parietaria) 2000 DPP/ml in patients with allergic rhinitis or rhinoconjunctivitis with or without seasonal asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary) ; Olea pollen allergy immunotherapy (Primary) ; Parietaria pollen allergy immunotherapy (Primary)
  • Indications Allergic asthma; Allergic rhinitis; Rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Laboratorios LETI
  • Most Recent Events

    • 28 Jan 2014 As per the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 24 Dec 2012 New trial record
    • 28 Nov 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01734265).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top